Reduction of death and nonfatal
myocardial infarction in patients undergoing CABG
surgery.
Cariporide is an Na+/H+ exchange inhibitor that functions to improve cellular integrity following events of cardiac ischemia and reperfusion (most commonly seen in non-heart beating donor organs). Cariporide is also used to prevent heart attacks in high-risk ischemic patients.
na–h exchange (nhe) represents an important mechanism for mediating such injury. nhe represents an important mechanism for the development of myocardial ischemic and reperfusion injury and inhibitors have been consistently shown to protect the ischemic and reperfused heart by correcting the ionic imbalance associated with this form of pathological insult. cariporide is a potent nhe inhibitor.
Cariporide is a selective inhibitor of the Na+/H+ exchanger subtype 1 (NHE-1), also known as the Na+/H+ antiporter. Cariporide has shown cardioprotective and antiarrhythmic effects, and has recently been investigated for anticancer activity.
cariporide concentration dependently inhibited the amiloride sensitive sodium influx in rabbit erythrocytes, reduced the swelling of human platelets caused by intracellular acidification, and delayed ph recovery in rat cardiomyocytes [1].
in anaesthetised rats undergoing coronary artery ligation intravenous and oral pretreatment with cariporide caused a dose dependent reduction or a complete prevention of ventricular premature beats, ventricular fibrillation, and ventricular tachycardia. the compound was well tolerated and neutral to circulatory variables [1].
0.05, 3 and 1000 μm for nhe1, nhe3 and nhe2, respectively
